Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

Table 1 Demographic characteristics of the participants (month 24 according-to-protocol persistence cohort)

		1xH5N1-AS	1xH5N1	2xH5N1-AS	2xH5N1	Total
		N = 86	N = 37	N = 81	N = 24	N = 228
Age	Mean ± SD	68.5 ± 6.32	68.6 ± 5.15	69.2 ± 6.48	67.7 ± 6.30	68.7 ± 6.18
	Range (min–max)	61–85	61–81	61–89	61–85	61–89
Gender: n (%)	Female	42 (48.8)	15 (40.5)	39 (48.1)	10 (41.7)	106 (46.5)
Race: n (%)	White-Caucasian/European heritage	85 (98.8)	36 (97.3)	74 (91.4)	22 (91.7)	217 (95.2)
	White-Arabic/North African heritage	1 (1.2)	1 (2.7)	7 (8.6)	2 (8.3)	11 (4.8)

N, number of participants in the specified group; n (%), number of participants with the specified characteristic; SD, standard deviation. Vaccination groups are: 1xH5N1-AS, single dose of the AS03_A-adjuvanted vaccine; 1xH5N1, single dose of the non-adjuvanted vaccine; 2xH5N1-AS, double dose of the AS03A-adjuvanted vaccine; 2xH5N1, double dose of the non-adjuvanted vaccine.

ISSN: 1745-6215